Our analyses raise a hypothesis that apparent differences in uric acid–lowering effects between the large SGLT2 inhibitor trials may reflect differences in trial population characteristics, specifically relating to diabetes and the level of kidney function. Here, SLC5A2 is linked to diabetes mellitus.